\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ examination\\:\\ fit\\ appearing\\ white\\ male\\ with\\ several\\ hundred\\ 2\\-5\\ mm\\ firm\\,\\ sharply\\ defined\\ xanthic\\ papules\\ on\\ the\\ flexural\\ surfaces\\ of\\ arms\\ and\\ legs\\,\\ anterior\\ aspect\\ of\\ his\\ thighs\\,\\ bilateral\\ axillae\\ and\\ upper\\ buttocks\\.\\ laboratory\\:\\ cholesterol\\:\\ 437\\ \\(desirable\\ \\<200\\ mg\\/dl\\)\\ glucose\\:\\ 248\\;\\ triglycerides\\:\\ 3764\\ \\(40\\-150\\ mg\\/dl\\)\\;\\ hbgalc\\:\\ 9\\.4\\ \\(4\\.0\\-6\\.7\\%\\)\\ \ \(0\)\
\-\ histopathology\\:\\ the\\ dermis\\ contains\\ a\\ diffuse\\ foamy\\ histiocytic\\ infiltrate\\ with\\ perivascular\\ accentuation\\.\\ there\\ is\\ a\\ scant\\ admixed\\ lymphocytic\\ infiltrate\\.\ \(0\)\
\-\ the\\ patient\\ was\\ referred\\ to\\ internal\\ medicine\\ for\\ management\\ of\\ type\\ v\\ familial\\ hyperlipidemia\\.\\ his\ \(0\)\
\-\ xanthoma\\ resloved\\ with\\ control\\ of\\ his\\ hypertriglyceridemia\\.\ \(1\)\
\-\ eruptive\\ xanthoma\\ \\(1997\\ uniformed\\ services\\ dermatology\\ seminar\\,\\ case\\#9b\\)\\ lcdrjames\\ m\\.\\ polo\\,\\ mc\\,\\ usn\ \(0\)\
\-\ this\\ is\\ a\\ 33\\ y\\/o\\ active\\ duty\\ white\\ man\\ who\\ developed\\ firm\\ 2\\-5\\ mm\\ papules\\ over\\ a\\ one\\ week\\ period\\ of\\ time\\ on\\ his\\ buttocks\\,\\ axillae\\,\\ flexural\\ surfaces\\ of\\ his\\ arms\\ and\\ legs\\ and\\ anterior\\ thighs\\.\\ the\\ papules\\ were\ \(0\)\
\-\ asymptomatic\\ except\\ for\\ mild\\ pruritis\\.\\	he\\ reported\ \(0\)\
\-\ excellent\\ health\\ prior\\ to\\ his\\ presentation\\ to\ \(1\)\
\-\ dermatology\\ and\\ denied\\ a\\ family\\ history\\ of\\ similar\ \(1\)\
\-\ \\ eruption\\.\ \(2\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ flexural\\:\\ 0\\.08728236063333167\ \(0\)\
\-\ papules\\:\\ 0\\.0825359686031438\ \(0\)\
\-\ his\\:\\ 0\\.07315511963307718\ \(0\)\
\-\ axillae\\:\\ 0\\.06954216786869745\ \(0\)\
\-\ xanthoma\\:\\ 0\\.06954216786869745\ \(0\)\
\-\ 2\\-5\\:\\ 0\\.06448448842546983\ \(0\)\
\-\ thighs\\:\\ 0\\.06188682244064318\ \(0\)\
\-\ buttocks\\:\\ 0\\.05762164505358918\ \(0\)\
\-\ surfaces\\:\\ 0\\.05502397906876253\ \(0\)\
\-\ infiltrate\\:\\ 0\\.050275730749337916\ \(0\)\
\-\ mg\\/dl\\:\\ 0\\.04760579444291116\ \(0\)\
\-\ arms\\:\\ 0\\.04725215006071236\ \(0\)\
\-\ legs\\:\\ 0\\.045800630514258145\ \(0\)\
\-\ dermatology\\:\\ 0\\.04565174063936171\ \(0\)\
\-\ xanthic\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ 3764\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ 40\\-150\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ hbgalc\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ 4\\.0\\-6\\.7\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ admixed\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ resloved\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ 9b\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ lcdrjames\\:\\ 0\\.043641180316665834\ \(0\)\
\-\ firm\\:\\ 0\\.04149055060081413\ \(0\)\
\-\ hundred\\:\\ 0\\.04020975863072551\ \(0\)\
\-\ 437\\:\\ 0\\.04020975863072551\ \(0\)\
\-\ hypertriglyceridemia\\:\\ 0\\.04020975863072551\ \(0\)\
\-\ polo\\:\\ 0\\.04020975863072551\ \(0\)\
\-\ \\:\\:\\ 0\\.03916793916799335\ \(0\)\
\-\ triglycerides\\:\\ 0\\.038202505620289054\ \(0\)\
\-\ histiocytic\\:\\ 0\\.038202505620289054\ \(0\)\
\-\ eruptive\\:\\ 0\\.038202505620289054\ \(0\)\
\-\ 248\\:\\ 0\\.03677833694478519\ \(0\)\
\-\ foamy\\:\\ 0\\.03677833694478519\ \(0\)\
\-\ accentuation\\:\\ 0\\.03677833694478519\ \(0\)\
\-\ desirable\\:\\ 0\\.03567366589867524\ \(0\)\
\-\ 9\\.4\\:\\ 0\\.03400796175698607\ \(0\)\
\-\ usn\\:\\ 0\\.03334691525884486\ \(0\)\
\-\ pruritis\\:\\ 0\\.032242244212734916\ \(0\)\
\-\ eruption\\:\\ 0\\.032242244212734916\ \(0\)\
\-\ scant\\:\\ 0\\.031770411639446175\ \(0\)\
\-\ mm\\:\\ 0\\.031110843136584212\ \(0\)\
\-\ fit\\:\\ 0\\.030234991202298455\ \(0\)\
\-\ 200\\:\\ 0\\.02906474972673296\ \(0\)\
\-\ perivascular\\:\\ 0\\.02881082252679459\ \(0\)\
\-\ white\\:\\ 0\\.02806043774962394\ \(0\)\
\-\ sharply\\:\\ 0\\.02732515622753549\ \(0\)\
\-\ dermis\\:\\ 0\\.027145118385105416\ \(0\)\
\-\ lymphocytic\\:\\ 0\\.026971398980099127\ \(0\)\
\-\ cholesterol\\:\\ 0\\.026803569516358133\ \(0\)\
\-\ hyperlipidemia\\:\\ 0\\.026183949996783844\ \(0\)\
\-\ familial\\:\\ 0\\.025900987552031626\ \(0\)\
\-\ m\\.\\:\\ 0\\.02479631650592168\ \(0\)\
\-\ mc\\:\\ 0\\.02479631650592168\ \(0\)\
\-\ excellent\\:\\ 0\\.024176696986347387\ \(0\)\
\-\ 1997\\:\\ 0\\.023713696699165093\ \(0\)\
\-\ histopathology\\:\\ 0\\.02362607503035618\ \(0\)\
\-\ seminar\\:\\ 0\\.02353997729415881\ \(0\)\
\-\ health\\:\\ 0\\.023455351386439498\ \(0\)\
\-\ uniformed\\:\\ 0\\.02329031960293657\ \(0\)\
\-\ v\\:\\ 0\\.02320982197485845\ \(0\)\
\-\ services\\:\\ 0\\.022825870319680856\ \(0\)\
\-\ glucose\\:\\ 0\\.022609025653055143\ \(0\)\
\-\ contains\\:\\ 0\\.022609025653055143\ \(0\)\
\-\ duty\\:\\ 0\\.02207331483800449\ \(0\)\
\-\ 33\\:\\ 0\\.021947979154913942\ \(0\)\
\-\ anterior\\:\\ 0\\.021790027958046906\ \(0\)\
\-\ except\\:\\ 0\\.021420208189279005\ \(0\)\
\-\ denied\\:\\ 0\\.020601772642618688\ \(0\)\
\-\ medicine\\:\\ 0\\.02006606182756803\ \(0\)\
\-\ \\;\\:\\ 0\\.020053675133193997\ \(0\)\
\-\ period\\:\\ 0\\.019778400288918124\ \(0\)\
\-\ control\\:\\ 0\\.019284839099694917\ \(0\)\
\-\ appearing\\:\\ 0\\.01880316132253254\ \(0\)\
\-\ defined\\:\\ 0\\.0178246666651362\ \(0\)\
\-\ family\\:\\ 0\\.01733818042041936\ \(0\)\
\-\ \\#\\:\\ 0\\.016592508014558853\ \(0\)\
\-\ similar\\:\\ 0\\.016592508014558853\ \(0\)\
\-\ \\<\\:\\ 0\\.016327057066840546\ \(0\)\
\-\ developed\\:\\ 0\\.01628745289522136\ \(0\)\
\-\ active\\:\\ 0\\.0161512813814103\ \(0\)\
\-\ referred\\:\\ 0\\.015963026947800205\ \(0\)\
\-\ management\\:\\ 0\\.015963026947800205\ \(0\)\
\-\ laboratory\\:\\ 0\\.015589563048782505\ \(0\)\
\-\ reported\\:\\ 0\\.01542116262661293\ \(0\)\
\-\ presentation\\:\\ 0\\.014571290269757833\ \(0\)\
\-\ week\\:\\ 0\\.014366412962020932\ \(0\)\
\-\ \\(\\:\\ 0\\.014304192598888328\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.014299962366317264\ \(0\)\
\-\ type\\:\\ 0\\.014260515981915398\ \(0\)\
\-\ internal\\:\\ 0\\.014182553818706789\ \(0\)\
\-\ \\)\\:\\ 0\\.014129459249768418\ \(0\)\
\-\ several\\:\\ 0\\.013599469483774195\ \(0\)\
\-\ aspect\\:\\ 0\\.013288573933085928\ \(0\)\
\-\ examination\\:\\ 0\\.01315060908650775\ \(0\)\
\-\ diffuse\\:\\ 0\\.012806967427600568\ \(0\)\
\-\ time\\:\\ 0\\.01194852092692729\ \(0\)\
\-\ he\\:\\ 0\\.01180290763382683\ \(0\)\
\-\ y\\/o\\:\\ 0\\.011715985296136835\ \(0\)\
\-\ one\\:\\ 0\\.011464016749062595\ \(0\)\
\-\ mild\\:\\ 0\\.01113986858381751\ \(0\)\
\-\ who\\:\\ 0\\.011029546579909417\ \(0\)\
\-\ prior\\:\\ 0\\.010861944416843383\ \(0\)\
\-\ over\\:\\ 0\\.010770507871980013\ \(0\)\
\-\ \\,\\:\\ 0\\.010721190713555937\ \(0\)\
\-\ physical\\:\\ 0\\.010378738958322961\ \(0\)\
\-\ bilateral\\:\\ 0\\.010266424402546753\ \(0\)\
\-\ upper\\:\\ 0\\.010208319333508506\ \(0\)\
\-\ man\\:\\ 0\\.010004613084603957\ \(0\)\
\-\ \\%\\:\\ 0\\.009867925907653504\ \(0\)\
\-\ a\\:\\ 0\\.00981682677768815\ \(0\)\
\-\ were\\:\\ 0\\.00960537790440555\ \(0\)\
\-\ case\\:\\ 0\\.009254972439936985\ \(0\)\
\-\ male\\:\\ 0\\.00764953236577957\ \(0\)\
\-\ for\\:\\ 0\\.007218892560818962\ \(0\)\
\-\ on\\:\\ 0\\.007167237746192357\ \(0\)\
\-\ to\\:\\ 0\\.00634259566994534\ \(0\)\
\-\ there\\:\\ 0\\.0062956215666583595\ \(0\)\
\-\ history\\:\\ 0\\.00584264622627269\ \(0\)\
\-\ is\\:\\ 0\\.005567235429551739\ \(0\)\
\-\ was\\:\\ 0\\.004892462981255875\ \(0\)\
\-\ this\\:\\ 0\\.0047581050164065995\ \(0\)\
\-\ and\\:\\ 0\\.004455668458718279\ \(0\)\
\-\ patient\\:\\ 0\\.0042405541134474655\ \(0\)\
\-\ of\\:\\ 0\\.004037260423692669\ \(0\)\
\-\ the\\:\\ 0\\.0027376095980916\ \(0\)\
\-\ with\\:\\ 0\\.0017376857835132138\ \(0\)\
\-\ \\.\\:\\ 0\\.0014059222216770803\ \(0\)\
